UPDATE CONCERNING COVID-19 (NOVEL CORONAVIRUS)

Due to the COVID-19 situation, the 21st International Conference on Alzheimer’s Drug Discovery will be hosted online.

This annual conference will showcase the innovative approaches of Alzheimer’s Drug Discovery Foundation’s (ADDF) funded scientists and their newest results. In addition to featuring ADDF’s portfolio, the program will also include guest presentations focusing on the latest research in the Alzheimer’s disease field.

The program features five sessions:

Novel Approaches for Neuroinflammation
Metabolic and Mitochondrial Approaches for Alzheimer’s Disease
Emerging Areas in Drug Development for Neurodegeneration
Neuroprotection, Synaptic Health and Neurotransmitters
Novel Biomarkers in Alzheimer’s Disease

The registration for this conference will be free though a brief form available at the Registration page.

OBJECTIVES

Highlight scientific progress on drug development programs aimed at treating Alzheimer’s disease and related dementias.
Increase opportunities for early career investigators and start-up companies to share information and resources.
Foster interdisciplinary and public-private partnerships and alliances.

}

SHORT PRESENTATION DEADLINE

The deadline to submit an entry for the Virtual Poster or the Start-up Forum presentations is August 21, 2020.

CONFERENCE HIGHLIGHTS

22 Speakers

Virtual Poster Presentations

Start-up Forum

Virtual Q&A

Ample sponsorship opportunities

Complimentary Registration

FOCUS

The purpose for this annual ADDF conference is to accelerate the development of innovative treatments for Alzheimer’s disease, related dementias and cognitive aging.

Attendees will see the diverse cutting-edge approaches ADDF scientists are undertaking and have opportunities for networking and partnership discussions with academic, industry, and foundation thought leaders.

AUDIENCE

The 2019 edition of this conference attracted close to 130 attendees from around the world. Attendees included:

Academic and industry scientists engaged in drug discovery research for neurodegenerative diseases and CNS
Business development and licensing professionals
Alliance management professionals
Venture capitalists and other investors
Graduate students, PhD candidates and post-doctoral fellows.